Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy.
作者信息
Newton N R, Leonard C H, Piecuch R E, Phibbs R H
机构信息
Pediatric Clinical Research Center, University of California, San Francisco 94143, USA.
出版信息
J Perinatol. 1999 Sep;19(6 Pt 1):403-6. doi: 10.1038/sj.jp.7200244.
OBJECTIVE
To compare the neurodevelopmental outcome of premature infants treated with recombinant human erythropoietin with that of control infants.
STUDY DESIGN
A total of 20 treated infants and 20 control infants who had completed randomized, double-blind, placebo-controlled studies of recombinant human erythropoietin as treatment for anemia of prematurity were followed for growth and developmental outcome in an intensive care nursery follow-up program. Infants were assessed by standard developmental tests.
RESULTS
No differences were found between groups for neurologic outcome, cognitive outcome, or growth patterns. All infants treated with recombinant human erythropoietin were neurologically normal. The rate of cognitive deficits was similar in the two groups.
CONCLUSION
In this small sample we did not see differences in neurodevelopmental outcome between infants treated with recombinant human erythropoietin and control infants.
Zotero 插件